Anixa Biosciences (ANIX) Assets Average (2011 - 2026)
Anixa Biosciences' (ANIX) quarterly Assets Average came in at $15.5 million in Q2 2026, down 13.76% YoY from $17.9 million in Q2 2025, and down 8.26% on a QoQ basis from $16.9 million in Q4 2025.
Anixa Biosciences (ANIX) Assets Average (2011 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 16 years of Assets Average data on file, last reported at $15.5 million in Q2 2026.
- Quarterly Assets Average fell 13.76% year-over-year to $15.5 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $15.5 million (down 13.76% YoY) and the FY2025 annual result came in at $18.8 million, down 20.04% from the prior year.
- Assets Average fell to $15.5 million in Q2 2026, from $16.9 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $35.7 million in Q1 2022 to a low of $15.5 million in Q2 2026.
- A 5-year average of $25.2 million and a median of $25.4 million in 2024 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2022 — Assets Average jumped 197.19% — and 2025, when it declined 27.84%.
- Tracing ANIX's Assets Average over 5 years: stood at $31.5 million in 2022, then slipped by 17.27% to $26.0 million in 2023, then retreated by 14.59% to $22.2 million in 2024, then fell by 24.2% to $16.9 million in 2025, then retreated by 8.26% to $15.5 million in 2026.
- The last three Assets Average figures came in at $15.5 million (Q2 2026), $16.9 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Anixa Biosciences | 123.62 Mn | 123.62 Mn | - | 15.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 15.47 Mn |
| Oct 31, 2025 | 16.87 Mn |
| Jul 31, 2025 | 17.31 Mn |
| Apr 30, 2025 | 17.94 Mn |
| Jan 31, 2025 | 20.25 Mn |
| Oct 31, 2024 | 22.25 Mn |
| Jul 31, 2024 | 23.63 Mn |
| Apr 30, 2024 | 24.86 Mn |
| Jan 31, 2024 | 25.45 Mn |
| Oct 31, 2023 | 26.05 Mn |
| Jul 31, 2023 | 27.09 Mn |
| Apr 30, 2023 | 27.95 Mn |
| Jan 31, 2023 | 29.36 Mn |
| Oct 31, 2022 | 31.49 Mn |
| Jul 31, 2022 | 32.68 Mn |
| Apr 30, 2022 | 34.02 Mn |
| Jan 31, 2022 | 35.75 Mn |
| Oct 31, 2021 | 36.66 Mn |
| Jul 31, 2021 | 37.78 Mn |
| Apr 30, 2021 | 26.55 Mn |